LSM family member 14BGenealiases: C20orf40 · FAM61B · FT005 · LSM13 · RAP55B · bA11M20.3
Q-omics provides the consensus-scored LSM14B profile across patient tissues and cancer cell-line models. LSM14B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LSM14B is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, LSM14B protein abundance shows 22,625 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, HNSC, and LSCC as cancer lineages where LSM14B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LSM14B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LSM14B survival associations across molecular data types. LSM14B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LSM14B RNA expression–survival associations across cancer types. High LSM14B expression shows unfavorable associations in LIHC, MESO, KICH and COAD, but favorable associations in UCS and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LSM14B RNA expression.
This table summarizes LSM14B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LSM14B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LSM14B shows higher tumor expression in HNSC, BLCA, COAD, KIRC, LIHC and LUSC. The HNSC box plot shows higher LSM14B RNA expression in tumor versus normal tissue (log2 FC = +0.886, t-test p < 0.001).
This table shows molecular features associated with LSM14B in patient tissues and cancer cell lines. In patient samples, LSM14B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LSM14B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
